wichy-shutterstock-com-1

Wichy / Shutterstock.com

29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More on this story

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More on this story

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Cooley adds ex-Gowling partner